NEUROCRINE BIOSCIENCES INC Payments to Acquire Debt Securities, Available-for-sale
NEUROCRINE BIOSCIENCES INC (NBIX) reported Payments to Acquire Debt Securities, Available-for-sale of $856.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $37.40M, a 88.13% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $819.50M, a 199.96% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $323.00M, a 3.59% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $408.50M, a 75.70% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.32B, a 24.97% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.06B, a 23.47% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for fiscal 2023 was $1.38B, a 122.13% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC payments to acquire debt securities, available-for-sale for fiscal 2022 was $621.20M, a 22.36% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $37.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $856.90M 10-Q · filed 2026-07-31 | $1.18B derived: sum of 3 quarters · filed 2026-07-31 | $1.59B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $819.50M 10-Q · filed 2026-05-05 | $1.14B derived: sum of 2 quarters · filed 2026-05-05 | $1.55B derived: sum of 3 quarters · filed 2026-05-05 | $1.87B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-12-31 | $323.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $731.50M derived: sum of 2 quarters · filed 2026-02-11 | $1.05B derived: sum of 3 quarters · filed 2026-07-31 | $1.32B 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $408.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $723.60M derived: sum of 2 quarters · filed 2026-07-31 | $996.80M 10-Q · filed 2025-10-28 | $1.31B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-06-30 | $315.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $588.30M 10-Q · filed 2026-07-31 | $900.10M derived: sum of 3 quarters · filed 2026-07-31 | $1.13B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $273.20M 10-Q · filed 2026-05-05 | $585.00M derived: sum of 2 quarters · filed 2026-05-05 | $817.50M derived: sum of 3 quarters · filed 2026-05-05 | $1.01B derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $311.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $544.30M derived: sum of 2 quarters · filed 2026-02-11 | $736.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.06B 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $232.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $424.20M derived: sum of 2 quarters · filed 2025-10-28 | $744.30M 10-Q · filed 2025-10-28 | $1.23B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $191.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $511.80M 10-Q · filed 2025-07-30 | $999.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.36B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $320.10M 10-Q · filed 2025-05-05 | $807.30M derived: sum of 2 quarters · filed 2026-02-11 | $1.17B derived: sum of 3 quarters · filed 2026-02-11 | $1.49B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $487.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $849.90M derived: sum of 2 quarters · filed 2026-02-11 | $1.17B derived: sum of 3 quarters · filed 2026-02-11 | $1.38B 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $362.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $686.50M derived: sum of 2 quarters · filed 2024-10-30 | $892.70M 10-Q · filed 2024-10-30 | $1.13B derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-06-30 | $323.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $530.00M 10-Q · filed 2024-08-01 | $763.30M derived: sum of 3 quarters · filed 2025-02-10 | $897.50M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-03-31 | $206.20M 10-Q · filed 2024-05-01 | $439.50M derived: sum of 2 quarters · filed 2025-02-10 | $573.70M derived: sum of 3 quarters · filed 2025-02-10 | $634.60M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2022-12-31 | $233.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $367.50M derived: sum of 2 quarters · filed 2025-02-10 | $428.40M derived: sum of 3 quarters · filed 2025-02-10 | $621.20M 10-K · filed 2025-02-10 | ||
| 2022-09-30 | $134.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $195.10M derived: sum of 2 quarters · filed 2023-10-31 | $387.90M 10-Q · filed 2023-10-31 | $529.30M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | $60.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $253.70M 10-Q · filed 2023-08-01 | $395.10M derived: sum of 3 quarters · filed 2024-02-09 | $670.70M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $192.80M 10-Q · filed 2023-05-03 | $334.20M derived: sum of 2 quarters · filed 2024-02-09 | $609.80M derived: sum of 3 quarters · filed 2024-02-09 | $899.20M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $141.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $417.00M derived: sum of 2 quarters · filed 2024-02-09 | $706.40M derived: sum of 3 quarters · filed 2024-02-09 | $800.10M 10-K · filed 2024-02-09 | ||
| 2021-09-30 | $275.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $565.00M derived: sum of 2 quarters · filed 2022-11-01 | $658.70M 10-Q · filed 2022-11-01 | $995.00M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-06-30 | $289.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $383.10M 10-Q · filed 2022-08-04 | $719.40M derived: sum of 3 quarters · filed 2023-02-09 | $830.00M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-03-31 | $93.70M 10-Q · filed 2022-05-04 | $430.00M derived: sum of 2 quarters · filed 2023-02-09 | $540.60M derived: sum of 3 quarters · filed 2023-02-09 | $657.20M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2020-12-31 | $336.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $446.90M derived: sum of 2 quarters · filed 2023-02-09 | $563.50M derived: sum of 3 quarters · filed 2023-02-09 | $735.50M 10-K · filed 2023-02-09 | ||
| 2020-09-30 | $110.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $227.20M derived: sum of 2 quarters · filed 2021-11-01 | $399.20M 10-Q · filed 2021-11-01 | $729.30M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2020-06-30 | $116.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $288.60M 10-Q · filed 2021-08-03 | $618.70M derived: sum of 3 quarters · filed 2022-02-11 | $849.90M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2020-03-31 | $172.00M 10-Q · filed 2021-05-05 | $502.10M derived: sum of 2 quarters · filed 2022-02-11 | $733.30M derived: sum of 3 quarters · filed 2022-02-11 | $852.90M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2019-12-31 | $330.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $561.30M derived: sum of 2 quarters · filed 2022-02-11 | $680.90M derived: sum of 3 quarters · filed 2022-02-11 | $797.20M 10-K · filed 2022-02-11 | ||
| 2019-09-30 | $231.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $350.80M derived: sum of 2 quarters · filed 2020-11-09 | $467.10M 10-Q · filed 2020-11-09 | $467.09M 10-Q · filed 2019-11-04 | $683.71M derived: sum of 4 quarters · filed 2021-02-05 | |
| 2019-06-30 | $119.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $235.90M 10-Q · filed 2020-08-03 | $235.90M 10-Q · filed 2019-07-29 | $452.51M derived: sum of 3 quarters · filed 2021-02-05 | $557.72M derived: sum of 4 quarters · filed 2021-02-05 | |
| 2019-03-31 | $116.30M 10-Q · filed 2020-05-06 | $332.91M derived: sum of 2 quarters · filed 2021-02-05 | $438.12M derived: sum of 3 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $216.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $321.82M derived: sum of 2 quarters · filed 2021-02-05 | $545.90M 10-K · filed 2021-02-05 | |||
| 2018-09-30 | $105.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $329.29M 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | $224.08M 10-Q · filed 2019-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |